FDA Aligns with REGENXBIO on Accelerated Approval Pathway for NAVSUNLI Gene Therapy in Hunter Syndrome
FDA reverses course and agrees to review existing data for NAVSUNLI gene therapy in Hunter syndrome.
/ 220 items
#andre↓
Getty Images Strikes Multi-Year Deal to Bring Licensed Photos into ChatGPT
Getty Images signed a deal with OpenAI to show its licensed photos and videos in ChatGPT search results.
Pfizer Announces Departure of CFO Dave Denton, Names Interim Successor
Cecile Guegan named Interim CFO as the company reaffirms its 2026 guidance.
Accenture Stock Plunges After Weak Q4 Guidance and Lowered Outlook
Accenture shares fell after weak guidance, but profits beat forecasts and it is boosting AI and cybersecurity bets.
Novocure Stock Plunges After Phase 3 TRIDENT Study Fails to Meet Primary Goal
Novocure’s Phase 3 TRIDENT trial failed to show survival benefit from earlier TTFields initiation in newly diagnosed glioblastoma.
Wall Street Initiates Coverage on IMMX, PRAX & RNA with Buy Ratings – Morgan Stanley Downgrades ENGN
BofA initiates coverage on IMMX with a Buy rating and $27 price target. RBC starts PRAX with Outperform ($449 PT), while Cantor begins coverage on RNA. Morgan Stanley downgrades ENGN to Underweight.